Alterity Therapeutics chairman reflects on two decades of progress as company enters new era

November 22, 2025 BioPharma

This is a preview of subscriber content

Subscribe now to continue reading.

Alterity Therapeutics (ASX:ATH) has marked a turning point in its corporate history, with longtime Chairman and company founder Geoffrey Kempler delivering his final address at the 2025 Annual General Meeting. …

Subscribe now to continue reading.

Latest Video

March PBAC agenda confirms a diverse range of therapies up for consideration
November 19, 2025 - Latest News
What if the system put people first? Imagining the institution we don’t have
November 20, 2025 - Latest News
Vertex secures TGA approval for next-generation cystic fibrosis therapy
November 19, 2025 - Latest News
If the system properly applied results in harm, then the problem is worse than we think
November 20, 2025 - Latest News
Radiopharm Theranostics appoints experienced industry executive to its board
November 19, 2025 - Australian Biotech

Alterity Therapeutics chairman reflects on two decades of progress as company enters new era

This is a preview of subscriber content

Latest Video

Most Read

March PBAC agenda confirms a diverse range of therapies up for consideration

What if the system put people first? Imagining the institution we don’t have

Vertex secures TGA approval for next-generation cystic fibrosis therapy

If the system properly applied results in harm, then the problem is worse than we think

Radiopharm Theranostics appoints experienced industry executive to its board

New Stories

Mesoblast to launch pivotal adult trial for cell therapy in severe steroid-refractory GVHD

Syntara launches Phase 2 trial aiming to teduce transfusion burden in myelodysplastic syndromes

Alterity Therapeutics chairman reflects on two decades of progress as company enters new era

Treasurer blocks US takeover of Mayne Pharma on national interest grounds

If the system properly applied results in harm, then the problem is worse than we think

Silence in response to unethical processes and outcomes is itself unethical

New analysis shows Telix's TLX250-CDx could change management of renal masses

Sign In

Alterity Therapeutics chairman reflects on two decades of progress as company enters new era

This is a preview of subscriber content

Latest Video

Most Read

March PBAC agenda confirms a diverse range of therapies up for consideration

What if the system put people first? Imagining the institution we don’t have

Vertex secures TGA approval for next-generation cystic fibrosis therapy

If the system properly applied results in harm, then the problem is worse than we think

Radiopharm Theranostics appoints experienced industry executive to its board

Follow Us

New Stories

Mesoblast to launch pivotal adult trial for cell therapy in severe steroid-refractory GVHD

Syntara launches Phase 2 trial aiming to teduce transfusion burden in myelodysplastic syndromes

Alterity Therapeutics chairman reflects on two decades of progress as company enters new era

Treasurer blocks US takeover of Mayne Pharma on national interest grounds

If the system properly applied results in harm, then the problem is worse than we think

Silence in response to unethical processes and outcomes is itself unethical

New analysis shows Telix's TLX250-CDx could change management of renal masses